Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sevelamer

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

- PMLiVE

Sanofi abandons inhaled insulin pact with Mannkind

Poor sales prompt return of Afrezza rights less than a year after its launch

- PMLiVE

Another setback for Teva’s laquinimod in MS

Side effects seen in two late-stage trials but development will continue

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

Sanofi reception

Sanofi and Boehringer in $20bn asset swap negotiations

Want to exchange their consumer health and veterinary interests

dengue fever mosquito

Sanofi gets first approval for dengue vaccine

Wins green light for Dengvaxia in Mexico

Sanofi Espoir Foundation appoints new president

Xavier Darcos succeeds Jean-François Dehecq

Teva Pharma logo

Teva buys into Heptares oral CGRP programme for migraine

Signs$410m alliance for early-stage candidates in potentially-lucrative drug class

Sanofi reception

Sanofi and AstraZeneca agree massive compound swap deal

Will exchange over 200,000 compounds in a new open innovation collaboration

Teva Pharma logo

TEVA’s tardive dyskinesia drug wins FDA breakthrough status

SD-809 to be given development incentives

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links